Description
Researchers at St. Jude developed an anti-CD7 chimeric antigen receptor (CD7 CAR) to use for treating hematologic cancers expressing the CD7 gene, which include lymphoblastic T-cell leukemia and lymphomas. The majority of T-cells, approximately 90%, express CD7 and are removed before transduction. The CD7 CAR is introduced into the remaining subset of T cells that do not naturally express CD7.
Keywords
chimeric antigen receptor, gene therapy vector, anti-CD7-CAR, T-cell malignancies
Granted Patents or Published Applications
International application published as WO 2017 213979 A1, US Pending
Related Scientific References
Licensing Opportunities
Please contact us if you are interested in licensing this technology. Contact: chad.riggs@stjude.org.
Related Links
- Activation of Prodrugs by Carboxylesterase (SJ-98-0001)
- Anti-GD2-BB-zeta Chimeric Receptor for Treating GD2+ Malignancies (SJ-13-0035)
- Antibodies to Tim4 for use as an Immune Enhancer and Cancer Therapeutic (SJ-18-0006)
- Association of Neuraminidase Regulated Exocytosis with Cancer Metastasis (SJ-11-0012)
- B7-H3-CAR 41BB ligand co-stimulation for solid tumors (SJ-19-0014)
- BCRP/ABCG2 as Stem Cell Marker (SJ-97-0016)
- CD33 CAR (SJ-17-0010)
- Chimeric gene and protein that can be used to create Optogranules: Light induced stress granules (SJ-18-0010)
- Chimeric IL13-MyD88 and PDL1-MyD88 receptors (SJ-20-0032)
- Development and Optimization of a Serotype-Independent Method of Adeno-Associated Virus (AAV) Harvest and Purification (SJ-16-0036)
- DNA Methylation Profile and Biomarkers for identifying functional T-cells (SJ-17-0002)
- DNMT3a knockout CAR T cells with Antigen Specificity (for solid tumors) (SJ-19-0024)
- Efficient generation of T-Cell Receptor (TCR) sequences in response to a variety of immune responses (SJ-19-0017)
- Erythroid Specific Promoter for Hematopoietic Disorders (SJ-16-0040)
- Extradomain-B Fibronectin (EDB)-targeted CAR Immune Cell Therapy (SJ-19-0029)
- Fibcd1 to treat or prevent muscle wasting (SJ-20-0008)
- Gene Therapy for Wiskott-Aldrich Syndrome (SJ-19-0012)
- Generation of Therapeutic T Cell Receptors for Fibrolamellar Cancer (SJ-19-0046)
- GMCSF.IL18 chimeric cytokine receptor for solid tumors (SJ-19-0028)
- GRP78 targeted adoptive cell therapy for surface GRP78+ (pediatrics and adult) cancer (SJ-19-0050)
- HMGA2 in Gene Therapy Vectors (SJ-16-0014)
- Hybrid Compounds to treat Gastrointestinal Infections (SJ-14-0019/UTA 14-01)
- IL35 Receptor (SJ-08-0039)
- Immune Cells with DNMT3A Gene Modifications (SJ-16-0009)
- Improved GD2 Ab for Neuroblastoma (SJ-17-0017)
- Improved Method to Produce Proteins to Treat Lysosomal Storage Disorders (SJ-01-0020)
- Interleukin-35 (IL-35) (SJ-06-0016)
- MAGE-A11 Inhibitor for cancer (SJ-20-0033)
- Method for Enhancing Recombinant Antibody Production (SJ-08-0032)
- Method for predicting T-cell development stage (and therapy success) (SJ-19-0033)
- Minimized Liver Specific Promoter for Improved Gene Expression in Gene Therapy Vectors (SJ-04-0024)
- miRNAs for Treating Cerebral Ventricle Enlargement in Schizophrenia Patients (SJ-19-0039)
- Myd88 and CD40 Costimulatory Domains for Chimeric Antigen Receptors (SJ-18-0021)
- New Method for Differentiating T-cells (SJ-18-0019)
- p53 Inhibitory Oligonucloeotides (SJ-09-0015)
- Protease Serine 21 (PRSS21) Targeted Immunotherapies (SJ-18-0043)
- Rapid Cloning of T Cell Receptors (SJ-16-0001)
- REGNASE-1 Gene Knockout or BATF Overexpression for Improving T-cell Function (SJ-19-0027, SJ-20-0007)
- Regulating p53 Translation and Function (SJ-05-0002)
- RIPK3 Fusion Protein for Treating Cancer and Autoimmunity (SJ-12-0036)
- Safety Test for Gene Therapy Vectors (SJ-15-0027)
- Use of Amylase or Maltose to Treat or Prevent Neurodegeneration (SJ-20-0009)
- Use of IL13 Promoter to Express Therapeutic Genes (SJ-18-0042)
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.